NCT05624099View on ClinicalTrials.gov

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2027

Conditions
Esophageal NeoplasmsEsophageal DiseasesDigestive System Neoplasms
Interventions
DRUG

camrelizumab

200mg intravenous drip d1q3w

DRUG

Paclitaxel drugs

150mg/m2 d1 q3w

DRUG

Platinum drug

Cisplatin, carboplatin, nedaplatin and other platinum drugs

RADIATION

Radiation

Dose: 5040cGy/28f

Trial Locations (1)

Unknown

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV